APA

Ramalingam S., Forster J., Naret C., Evans T., Sulecki M., Lu H., Teegarden P., Weber M. R. & Belani C. P. (20080522). Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chicago

Ramalingam Suresh, Forster Judy, Naret Cynthia, Evans Terry, Sulecki Matt, Lu Haolan, Teegarden Paola, Weber Martin R and Belani Chandra P. 20080522. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Harvard

Ramalingam S., Forster J., Naret C., Evans T., Sulecki M., Lu H., Teegarden P., Weber M. R. and Belani C. P. (20080522). Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MLA

Ramalingam Suresh, Forster Judy, Naret Cynthia, Evans Terry, Sulecki Matt, Lu Haolan, Teegarden Paola, Weber Martin R and Belani Chandra P. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 20080522.